Expression vector of human STAT6.
Alternative name | SET-0181_9 |
---|---|
Clone info. | Expression vector of human STAT6. Expression was confirmed by Western blotting with anti-FLAG antibody. |
Comment | Derived from Sugano BC075852. PCR cloning, forward primer: atgtctctgtggggtctggtctcc; reverse primer: gatcaccaactggggttggc. |
Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
Size of vector backbone | 5.5 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
Growth conditions | 37C, LB+Amp |
Gene/insert name | Human STAT6 cDNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。 付加的使用条件: pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
Catalog # | Resource name | Shipping form | Fee |
---|---|---|---|
RDB06383 | pCMFlag_hsSTAT6 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pCMFlag_hsSTAT6 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06383). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB06383_A3Ir.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: Sequence file: RDB06383_A3Ira.seq ![]() |
---|
>06383_06383_A3Ir_2_CMV-Foward_A04_01.ab1 1 AGTTCCCCTC CGCCCCATTG ACGCAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT 61 AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC 121 GACTCACTAT AGGGAGACCC AAGCTGAATT CACCATGGAC TACAAGGACG ATGACGATAA 181 GGCGGCCATG TCTCTGTGGG GTCTGGTCTC CAAGATGCCC CCAGAAAAAG TGCAGCGGCT 241 CTATGTCGAC TTTCCCCAAC ACCTGCGGCA TCTTCTGGGT GACTGGCTGG AGAGCCAGCC 301 CTGGGAGTTC CTGGTCGGCT CCGACGCCTT CTGCTGCAAC TTGGCTAGTG CCCTACTTTC 361 AGACACTGTC CAGCACCTTC AGGCCTCGGT GGGAGAGCAG GGGGAGGGGA GCACCATCTT 421 GCAACACATC AGCACCCTTG AGAGCATATA TCAGAGGGAC CCCCTGAAGC TGGTGGCCAC 481 TTTCAGACAA ATACTTCAAG GAGAGAAAAA AGCTGTTATG GAACAGTTCC GCCACTTGCC 541 AATGCCTTTC CACTGGAAGC AGGAAGAACT CAAGTTTAAG ACAGGCTTGC GGAGGCTGCA 601 GCACCGAGTA GGGGAGATCC ACCTTCTCCG AGAAGCCCTG CAGAAGGGGG CTGAGGCTGG 661 CCAAGTGTCT CT // |
Primer: Sequence file: RDB06383_A3Irb.seq ![]() |
>06383_06383_A3Ir_2_Sp6_B04_04.ab1 1 CCGAGAATCT GCTCGAGCGG CCGATCACCA ACTGGGGTTG GCCCTTAGGT CCATGTGGGA 61 CATTGAGATC CCAGATTGCC CATAGTGGGA GGGCTGCAGG AGGGGCTGTG CCCCCAAGGA 121 CCCTCCCCCC GACTCCCCTT GCCCCTCCAG GAGAAGCTTA GTGAGGTCCT GTTCAGTGGG 181 AGGCAGCAGA GGAGGGAATA TGTCTTCACC AATCCAAGTG CCCTGAGGAA ACGCTGTCAC 241 TGGCTGGCTC AGGCAGCTGT CTTCCACCAT GGTCACATCT GAGCAGAGCA GGGGGTCAGG 301 GCTGGACACA GCATGCTCCT GAGGCTGGCA CGGCAGCAGG CCCTGGGGGT GAGGCTGGTC 361 AAAGGGCAGG CTCATCTGGC CCAGGCTGGG GGGCATCTGC AGGTGAGGCT CCTGGAAGGC 421 TGACAACACG TTGACTGATT CTTCTGGGGA GAGGCCTTGA TACGGGGGGA TGGAGTGAGA 481 GTGTGGTGGG TACACCTGGG GCACCATATC TGGGCCAAGC TGCATGCTCA TGGAGGAATC 541 AGGGGCCATT CCAAGGTCAT AAGAAGGCAC CATGGTAGGC ATCTGGAGCT CTGGGGTAGG 601 AAGTGGTTGG TCCCTTTCCA CGGTCATCTT GATGGTAGCT GGGACATAAC CCCTGCCATC 661 CTTACCCATC TGTTC // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content